Navigation Links
Positive Results from Phase 2 Trial of Mesoblast's Adult Stem Cell Therapy Presented at the American Heart Association Annual Meeting
Date:11/14/2011

at 6 months, p=0.015) and improved functional capacity (gain of 52.6 meters over 6 minutes' walk compared with controls at 12 months, p=0.06).

After 12 months, 40% of all treated patients had reverted to class I NYHA status compared with 14% of all controls, and this effect remained when patients were matched for the presence of class II status at baseline. The group who received the 25M MPC dose showed a significant 8.9 point improvement in ejection fraction over controls at 3 months (p=0.008), with a sustained but less pronounced effect over 12 months. In contrast, the group who received 150M MPC did not show improved ejection fraction, suggesting that the positive effects of this dose on clinical outcomes, remodeling, and functional capacity may be due to other mechanisms such as anti-fibrosis.

"These clinical findings are the first using any cell therapy in heart failure patients to show a concordant positive effect on clinical outcomes, cardiac remodelling, and functional capacity, the three key parameters in congestive heart failure.  Together, they indicate that a single 150 million dose of Revascor™ may significantly reduce both heart failure hospitalizations and death in these very sick patients who have such a poor prognosis despite maximal existing therapies," Dr Perin said.  

"Based on their defined product characterization, batch to batch consistency, immediate availability, and lack of clinically relevant immunogenicity, MPCs appear to be an ideal cell type to provide a new level of patient care in congestive heart failure.  We look forward to progressing the Revascor™ clinical program into Phase 3," Dr Perin added.

Revascor™ is being jointly developed by Mesoblast and its strategic alliance partner, Teva Pharmaceutical Industries Ltd.  

Teva's Corporate Vice President Global Branded Products, Kevin Buchi, said: "These independently-reviewed results serve to reinforce Teva's commi
'/>"/>

SOURCE Mesoblast
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Positive Data for Nektars New Mu-Opioid Analgesic Molecule to Treat Acute Pain Highlighted at Neuroscience 2011
2. Ampio Pharmaceuticals Announces Positive Results on Ampion™ Trial for Relief of Nasal Inflammation
3. Sanofi and Regeneron Report Positive Preliminary Phase 2 Program Results for Anti-PCSK9 Antibody in Hypercholesterolemia
4. Sinovac Reports Positive Preliminary Phase II Clinical Trial Results for EV71 Vaccine Against Hand, Foot and Mouth Disease
5. NeuroDerm Announces Positive Results of a Phase II Study of ND0611 Dermal Patch in Patients with Parkinsons Disease
6. Micell Technologies Announces Positive Preliminary Data from DESSOLVE I Study of MiStent® Sirolimus Drug Eluting Coronary Stent System
7. Positive Interim Results from Interferon-Free Phase 2b SOUND-C2 Study with Boehringer Ingelheims Two Investigational HCV Direct Acting Antivirals Presented at AASLD
8. Halozyme Therapeutics Announces Positive Results From Enzyme-Augmented Insulin Pump Trial
9. Positive Phase 2b Results with Sarilumab in Rheumatoid Arthritis to be Presented as a Late-Breaking Poster at the 2011 American College of Rheumatology Annual Meeting
10. Pharmaxis Announces Major Milestone: Positive Bronchitol Opinion for Europe
11. Halozyme Announces Positive Results from Roches Subcutaneous Herceptin Phase 3 Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... , Sept. 19, 2014 /PRNewswire-iReach/ -- ... to 2020″, provides key market data ... devices market. The report provides value, ... volume (in units) within market categories ... Sigmoidoscopes, Esophagoscopes & Gastroscopes, Duodenoscopes, Laparoscopes, ...
(Date:9/19/2014)... Sept. 19, 2014  For Cloud Pharmaceuticals, Inc., ... and development, partnering is an integral part of ... design new drugs and identify early stage, preclinical, ... further their development. The company also partners with ... this business model, Cloud Pharmaceuticals will be participating ...
(Date:9/19/2014)... Mich. , Sept. 19, 2014  Diplomat, the ... of David Dreyer to the Board of ... independent director and will also serve as chair of ... almost 30 years of accounting, financial, compliance and operating ... Mr. Dreyer has served as chief financial officer, chief ...
Breaking Medicine Technology:United States General Surgery Devices Market to 2020 - Endoscopy, Bariatric Surgery, Aesthetic Lasers and Energy, Biopsy Devices, Hernia Repair, Non-Vascular Stents 2United States General Surgery Devices Market to 2020 - Endoscopy, Bariatric Surgery, Aesthetic Lasers and Energy, Biopsy Devices, Hernia Repair, Non-Vascular Stents 3United States General Surgery Devices Market to 2020 - Endoscopy, Bariatric Surgery, Aesthetic Lasers and Energy, Biopsy Devices, Hernia Repair, Non-Vascular Stents 4United States General Surgery Devices Market to 2020 - Endoscopy, Bariatric Surgery, Aesthetic Lasers and Energy, Biopsy Devices, Hernia Repair, Non-Vascular Stents 5Cloud Pharmaceuticals Announces Partnering Sessions and Presentation Schedule 2David Dreyer Appointed to Diplomat Board of Directors 2
(Date:9/19/2014)... On September 16, Camino Public Relations ... and Top Places to Work in PR Awards Luncheon ... received honorable mentions in two categories for “Multicultural Campaign” ... elevating Latina voices in the media. , "We're honored ... part of its efforts to improve the national conversation ...
(Date:9/19/2014)... (PRWEB) September 19, 2014 Hastings and Hastings, ... years in the industry, announces a record number of visitors ... a wide variety of serious injury cases as well as ... with dog bite related accident cases and others. Having served ... Hastings has stood the test of time when it comes ...
(Date:9/19/2014)... 19, 2014 Visiting Nurse Association (VNA) ... health care, hospice and palliative care and community-based care, ... Opening Bell yesterday at the New York Stock Exchange. ... and social entrepreneur to care for immigrant families suffering ... always worked to meet the urgent healthcare needs of ...
(Date:9/19/2014)... York, New York (PRWEB) September 19, 2014 ... in a transvaginal mesh lawsuit ( http://www.transvaginalmeshlawsuithelp.com/ ) ... state court next month, Bernstein Liebhard LLP reports. ... in Dallas District Court, the company asserts that claims ... the Texas Civil Practice and Remedies Code, a section ...
(Date:9/19/2014)... 19, 2014 (HealthDay News) -- Your brain structure could help ... new study suggests. Researchers at Yale University found those ... as the parietal cortex may be more likely to engage ... area. , , The study, funded by the U.S. National ... and women living in the Northeast. The researchers sought to ...
Breaking Medicine News(10 mins):Health News:Camino Public Relations Honored for Raising Latina Voices in National Health Care, Immigration Debates 2Health News:Hastings And Hastings Announces a Record Number of Visitors to Its New Phoenix Personal Injury Website 2Health News:NJ Largest Home Healthcare Not-for-Profit Joins Deutsche Bank to Ring NYSE Opening Bell 2Health News:NJ Largest Home Healthcare Not-for-Profit Joins Deutsche Bank to Ring NYSE Opening Bell 3Health News:Transvaginal Mesh Lawsuit Defendant Moves For Summary Judgment in Case Scheduled for Upcoming Texas Trial, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuit Defendant Moves For Summary Judgment in Case Scheduled for Upcoming Texas Trial, Bernstein Liebhard LLP Reports 3Health News:Transvaginal Mesh Lawsuit Defendant Moves For Summary Judgment in Case Scheduled for Upcoming Texas Trial, Bernstein Liebhard LLP Reports 4Health News:Brain Structure Might Help Predict Risky Behavior 2
... Anchorage-independent Assay for Screening Compounds for Inhibition of ... Inc. announced today that it has received U.S. ... Cancer BioChip System (CBCS) for the identification and ... in vitro setting with great clinical ...
... combination therapy of daily consensus interferon (CIFN) and ribavirin is ... do not respond to standard therapy. The treatment works particularly ... to a new study in the June issue of ... on behalf of the American Association for the Study of ...
... people are pulling back on cosmetic procedures during the recession, ... laser vein removal . Unfortunately, most people who ... realize that beautiful, healthy legs are within their budget since ... varicose veins removed promptly, individuals are at ...
... Teel as President of Premier Anesthesia, a national anesthesia management company ... ... May 28, 2009 -- Jackson Healthcare announces the appointment ... management company based in Atlanta, Georgia., , , , ,"Having been ...
... took a major step forward to save lives and ... $1 per pack surcharge into law. Additionally, the governor ... smoking cessation services for Floridians, including monies for the ... fourth lowest in the nation. When the surcharge goes ...
... the Sisters of Charity Health System continues its strategic ... commitment to growing its physician collaboration strategies. Key to ... Jr. in the new position of senior vice president ... position May 28. "As we move through this transition ...
Cached Medicine News:Health News:Falcon Genomics Awarded Patent for Innovative Cancer Test 2Health News:New treatment option for patients with chronic hepatitis C 2Health News:Get Sexy Summer Legs From Renaissance Laser and Vein Institute (laserandveinclinic.com) Courtesy of Your Health Insurance 2Health News:Kerry Teel Named President of Premier Anesthesia 2Health News:Kerry Teel Named President of Premier Anesthesia 3Health News:Florida's $1 Cigarette Tax Increase a Big Win for Public Health 2Health News:Florida's $1 Cigarette Tax Increase a Big Win for Public Health 3Health News:Sisters of Charity Health System Appoints Orlando L. Alvarez Jr. to Head Physician Strategy and Business Development 2Health News:Sisters of Charity Health System Appoints Orlando L. Alvarez Jr. to Head Physician Strategy and Business Development 3
Immuno-turbidimetric Assay of D-Dimer by STA© Analyzers. Microlatex particles coated with two different mouse monoclonal anti-human D-Dimer antibodies....
Detection of Lupus Anticoagulants. Freeze-dried hexagonal phase phos-phatidylethanolamine; normal plasma with heparin inhibitor; PTT-LS reagent of cephalin and particulate siliceous activator;all fre...
... Protein C Activity by STA© ... of Protein C; highly purified ... venom for specific activation of ... activator selected specially for protein ...
Immuno-turbidimetric Assay for Protein S Antigen. Suspension of microlatex particles coated with specific antibodies....
Medicine Products: